Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Genetics of adverse drug reactions

A postgraduate research opportunity at the University of Otago.

Details

Close date
Tuesday, 22 August 2017
Academic background
Health Sciences, Sciences
Host campus
Christchurch
Qualifications
Honours, Master’s
Department
Pathology (Dunedin)
Supervisors
Professor Martin Kennedy, Dr Simran Maggo, Associate Professor Matthew Doogue

Overview

Pharmacogenomics is the study of how genes influence a patient's responses to drugs. This research area is helping to clarify how genetic differences contribute to the risk of side effects or failure of drug treatment, and how we might better tailor treatment to each patient, leading to improved safety and effectiveness. We have a number of possible research projects available to study the genetic/genomic basis of medication induced adverse reactions.

Our previous and current pharmacogenes of interest include:

  • CYP2D6, CYP2C19, TPMT, HLA and POR

Medication-adverse event pairs include:

  • Statin-induced myopathy
  • SSRI/SNRI-induced adverse events
  • ACEi-cough/angioedema
  • Hyponatraemia due to PPIs, SSRIs and thiazides
  • PPI induced interstitial nephritis
  • Metoclopramide induced dystonia

Contact

Professor Martin Kennedy
Email   martin.kennedy@otago.ac.nz